From the initiation of anti-PD-1 treatment, factors such as tumour mutational burden, specific mutations (e.g., STK11, KEAP), clonal architecture, aneuploidy, immune-escape mechanisms, and interferon-γ signalling pathways have all been linked to resistance [26]. Here, PDCD1 is linked to neoplasm.